Takeda / Baxalta Brooklyn Park MN

Baxalta U.S. Inc. retained PharmaBioSource Realty, LLC as its exclusive real estate broker to market and sell a 215,000-square-foot mammalian cell culture manufacturing facility located in Brooklyn Park, Minnesota. Baxalta, a recent spin-out from Baxter International, made the strategic decision to divest the biologics API facility as part of a broader manufacturing network consolidation. The site sat on 29 acres approximately 10 miles north of Minneapolis and included 2 x 10,000L and 2 x 1,000L bioreactors, making it a rare large-scale biologics asset that offered strategic buyers meaningful reductions in both capital costs and time to market. The scale and specialized capability restricted the potential buyer pool to global biologics operators with the appetite and technical readiness to absorb an asset of this scale.

PharmaBioSource Realty engaged the pharmaceutical and biotech industry to market and sell the Brooklyn Park facility to a strategic acquirer. We drew on real estate and technical expertise, along with our extensive contacts within the life sciences industry, to identify qualified potential buyers for the site.

Services provided by the PharmaBioSource Realty team:

• Facility assessment
• Prep for sale
• Creation of introductory project teaser
• Target identification and marketing
• Creation of a site management presentation
• Support in developing a data room
• Managed confidentiality agreements
• Hosted site visits and meetings with Baxalta management
• Supported buyer due diligence
• Contract documents
• Deal structure and negotiations
• Closing

PharmaBioSource Realty solicited multiple offers for the Brooklyn Park facility and identified Takeda — a research-based global pharmaceutical company based in Japan — as the acquirer. The transaction closed in just six months from initial engagement.